Genzyme Closes Ilex Deal After FTC Orders “Creative” Campath Divestiture
Executive Summary
Genzyme will be precluded from any involvement with Campath (alemtuzumab) in the organ transplant rejection therapy market under a consent order with the Federal Trade Commission allowing the company to complete the acquisition of Ilex
You may also be interested in...
Off-Label Use “Predictions” May Be Scrutinized, Prosecutor Sheehan Says
Companies may include predictions of off-label use in their business plans but should be careful not to cross the line into encouraging off-label promotion, Philadelphia Associate U.S. Attorney James Sheehan suggested at a Food and Drug Law Institute advertising conference in Washington, D.C
Genzyme Enters Oncology Market Via $1 Bil. Acquisition Of Ilex
Genzyme will pay $1 bil. for its first marketed oncology therapeutic agent through the acquisition of Ilex Oncology
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011